COO · Cooper Companies, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| free cash flow | 96.4M | Second Quarter 2026 | — |
|
|
|||
| Non-GAAP operating margin non-GAAP | 27% | Second Quarter 2026 | — |
|
|
|||
| Capital expenditures | $102.2M | first quarter | — |
| Cash provided by operations | $260.9M | first quarter | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COO
this stock
Cooper Companies, Inc.
|
$13.71B | -14.3% | +18.4% | 60.1 | 4.1% |
|
ISRG
Intuitive Surgical Inc
|
$119.23B | -41.4% | +20.5% | 38.8 | 1.9% |
|
MDLN
Medline Inc.
|
$50.91B | -7.7% | +11.5% | — | 2.2% |
|
BDX
Becton Dickinson & Co
|
$43.08B | +1.6% | +8.2% | 59.4 | 3.8% |
|
ALC
Alcon Inc
|
$33.12B | -14.7% | +10.5% | — | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COO | -3.9% | +2.0% | -12.6% | -2.1% | -14.3% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -2.3% | +1.4% | -19.0% | -0.9% | -22.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.